A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin

Autor: René dePont Christensen, Bente Lund, Mansoor Raza Mirza, Anders Mellemgaard, Nina Keldsen, Jacob Christian Lindegaard, Kamma Bertelsen

Publikováno v: Mirza, M R, Lund, B, Lindegaard, J C, Keldsen, N, Mellemgaard, A, Christensen, R D & Bertelsen, K 2010, ' A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin ', Gynecologic Oncology, vol. 119, no. 1, pp. 26-31 . https://doi.org/10.1016/j.ygyno.2010.06.022

Objective Treatment of epithelial ovarian cancer patients relapsing with a short treatment-free interval (TFI) after prior chemotherapy is unsatisfactory. This phase II trial evaluated the activity and feasibility of pegylated liposomal doxorubicin (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27193677fc6d4cb62588c58fde908b3d
https://doi.org/10.1016/j.ygyno.2010.06.022

Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study

Autor: Nina Keldsen, Anders Jakobsen, Ignace Vergote, Hanne Havsteen, Kamma Bertelsen

Publikováno v: Keldsen, N, Havsteen, H, Vergote, I, Bertelsen, K & Jakobsen, A 2003, ' Altretamine (hexamethylmelamine) in the treatment of platinumresistant ovarian cancer : a phase II study ', Gynecologic Oncology, vol. 88, pp. 118-122 .

Objective To evaluate the activity of oral Altretamine in women with epithelial ovarian carcinoma who responded (PR or CR) to first line chemotherapy but relapsed within 6 months. The protocol was later amended to include patients with relapse within

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624133348f2f0e65015ac4b913df8684
https://doi.org/10.1016/s0090-8258(02)00103-8

Intergroup collaboration in ovarian cancer: a giant step forward

Autor: Elizabeth Eisenhauer, Claes G. Tropé, G. C.E. Stuart, S. B. Kaye, Jan B. Vermorken, Martine Piccart, Peter Harper, Kamma Bertelsen, Kenneth D. Swenerton, J. Cassidy, M. K. B. Parmar

Publikováno v: Annals of oncology

The rather slow evolution of so-called "optimal chemotherapy" for ovarian cancer is the result of suboptimal randomised clinical trials, not having the statistical power to identify truly superior regimens, and of the lack of systematic comparisons o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03aacc6f5ec7faf8f84b80c4b892eccd
https://doi.org/10.1016/s0923-7534(20)31490-3

[Untitled]

Autor: Kamma Bertelsen, Seija Grénman, G. J. S. Rustin

Publikováno v: Annals of Oncology. 10:17-20

Documentation for the optimal duration of first-line chemotherapy in advanced ovarian cancer is limited. Three randomised trials have compared 5-6 cycles with 8, 10 and 12 cycles respectively. None of the studies showed benefit of chemotherapy beyond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::68c56ed4bb67812848851b4938b7b944
https://doi.org/10.1023/a:1008399132535

Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study

Autor: Kamma Bertelsen, Estrid S. Hansen, Gitte Ørtoft

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 23(8)

Objectives In 2 prospective nationwide studies, the Danish Endometrial Cancer Study demonstrated that postoperative radiotherapy (RT) could be omitted in low- and intermediate-risk stage I patients without loss of survival when evaluated after 5 year

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41d5b566ef92bfee7f4dea7dc7f67084
https://pubmed.ncbi.nlm.nih.gov/24257557